Gefitinib Reactions 1680, p151 - 2 Dec 2017 Development of acquired resistance: case report A patient [age and sex not stated] received gefitinib for lung adenocarcinoma and developed acquired resistance to The patient, who had a history of lung adenocarcinoma, was started on gefitinib [route and dosage not stated]. A cell growth inhibition test was performed with gefitinib and afatinib. The lung adenocarcinoma cell line (G719S-GR) was established from the malignant pleural effusion. The test showed human epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) resistance in G719S-GR cells with an LC50 of greater than 100µM for either afatinib or gefitinib [time to reaction onset not stated], and indicated that the tumour developed an acquired resistance from the initial treatment with gefitinib. The test result also showed the G719S-GR cells resistant to EGFR-TKI in vitro. The next generation sequencing (NGS) revealed G719S-GR cells harbor EGFR mutations of E709A and G719S along with the amplification of EGFR, MYC, interleukin 7 receptor (IL7R) and fibroblast growth factor receptor 1 (FGFR1) locus. Additionally, the loss of tuberous sclerosis 1 (TSC1), phosphatase and tensin homolog (PTEN) and cyclin-dependent kinase inhibitor 2A (CDKN2A) were observed in G719S-GR cells. The loss PTEN was considered to be the mechanism for the development of acquired resistance to gefitinib. Author comment: "We established a lung adenocarcinoma cell line (G719S-GR) from the malignant pleural effusion of a patient whose tumor developed acquired resistance from initial treatment with gefitinib." Osoegawa A, et al. Acquired resistance to EGFR-TKI in an uncommon G719S EGFR mutation. Cancer Research 77 (Suppl. 13): abstr. 4107, No. 13, Jul 2017. Available from: URL: [abstract] - Japan 803284992 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial